Targeting central regulation of oncogenic signaling through inhibition of translation initiation complex eIF4F

通过抑制翻译起始复合物 eIF4F 靶向致癌信号传导的中枢调节

基本信息

项目摘要

Cancer is a widespread group of diseases with deleterious effects on society with regard to human health and financial burden. Furthermore, the development of chemoresistance to first-line therapies is responsible for the majority of deaths (over 90%) in tumor patients. Elevated protein synthesis is a critical trait that is associated with genesis, poor prognosis, and drug resistance in many types of human cancers. Eukaryotic initiation factor 4F (eIF4F), a cap-dependent mRNA translation initiation complex forms a central node for frequently upregulated oncogenic pathways such as Myc, Ras, and PI3K-AKT-mTOR. An essential requirement for the assembly and operation of the eIF4F translational machinery is the interaction between subunits eIF4E and eIF4G. Inhibition of this protein-protein interaction (PPI) has been recently demonstrated as a viable approach to target translation initiation. However, the published PPI inhibitors suffer from low affinity and solubility issues along with off-target effects. Thus, our goal is to develop novel drug-like and selective small molecule inhibitors of eIF4E/eIF4G interaction. Our hypothesis is that the canonical motif-binding site on the surface of eIF4E can be targeted via mimicry of eIF4G. Our computational approach identified novel scaffolds that could potentially inhibit this interaction by targeting the hot-spot residues on the surface of eIF4E. These compounds are devoid of PAINS characteristics and facilitate scanning of 3D space on the eIF4E surface. To test our hypothesis, we will pursue three specific aims. Aim 1 will focus on the design and synthesis of novel PPI inhibitors with drug-like properties. These synthesized compounds will be assessed in fluorescence polarization and pull-down assays to determine the eIF4E/eIF4G interaction inhibition profile in Aim 2. Aim 3 will evaluate the cellular effects by testing the high- affinity compounds in a dual luciferase assay. This assay enables the determination of inhibition of cap- dependent versus cap-independent translation. Further, the selected compounds will be tested for their anti- proliferative effects on human cancer cell lines.
癌症是一组广泛存在的疾病,对人类健康和社会产生有害影响

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bhargav Ashokbhai Patel其他文献

Bhargav Ashokbhai Patel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

基于多重精准选择性碳氢官能化合成策略的抗A549/HepG2活性先导化合物发现及其作用靶标研究
  • 批准号:
    22007020
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
导向抗HepG2/A549先导化合物发现和结构优化的多重精准选择性C-H键官能化反应研究
  • 批准号:
  • 批准年份:
    2019
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
内蒙古白云鄂博稀土矿区大气可吸入颗粒物对A549细胞毒理研究
  • 批准号:
    81473017
  • 批准年份:
    2014
  • 资助金额:
    66.0 万元
  • 项目类别:
    面上项目
用于识别癌细胞A549的磁共振和荧光双功能探针的研究
  • 批准号:
    21305156
  • 批准年份:
    2013
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目
DNA甲基化参与非小细胞肺癌细胞(A549/DDP)顺铂耐药的研究
  • 批准号:
    81101650
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
白藜芦醇诱导人肺癌A549细胞PML蛋白自噬性降解的机制研究
  • 批准号:
    81172089
  • 批准年份:
    2011
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
hTERT启动子调控下CD137L在肺癌A549细胞中的表达及其抑制肿瘤免疫的实验研究
  • 批准号:
    81172140
  • 批准年份:
    2011
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目
Id3在肺腺癌中的表达分析及其对A549肺腺癌细胞增殖影响的机制研究
  • 批准号:
    81171652
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
姜黄素调控肺腺癌A549细胞株SP细胞Wnt信号通路的研究
  • 批准号:
    81001578
  • 批准年份:
    2010
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
PTEN抑制A549肺癌细胞趋电性及调控直流电场对肺癌转移诱导的研究
  • 批准号:
    81000938
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Toxicity evaluation and mechanism of acid gas generation from halogen fire extinguisher by combination of FTIR analysis and human cell A549 viability
结合 FTIR 分析和人体细胞 A549 活力评价卤素灭火器产生酸性气体的毒性和机制
  • 批准号:
    26350465
  • 财政年份:
    2014
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An in vitro system has identified a factor released only by Pseudomonas aeruginosa biofilm and not planktonic bacteria that interacts with A549 lung epithelia and LL-37 pre-treatment of biofilms minimizes its effects.
体外系统已鉴定出仅由铜绿假单胞菌生物膜而不是浮游细菌释放的与 A549 肺上皮细胞相互作用的因子,并且生物膜的 LL-37 预处理可最大限度地减少其影响。
  • 批准号:
    263429
  • 财政年份:
    2012
  • 资助金额:
    $ 18.06万
  • 项目类别:
Mechanism for the release of IL-8 from A549 cells treated with alpha-toxin.
用 α 毒素处理的 A549 细胞释放 IL-8 的机制。
  • 批准号:
    21790431
  • 财政年份:
    2009
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Transcriptional regulation mechanisms of arylhydrocarbon receptor(AhR), Arnt and E2F genes on proliferation process in A549 cells as promoter activity in carcinogenesis by dioxin
芳基烃受体(AhR)、Arnt和E2F基因对A549细胞增殖过程的转录调控机制作为二恶英致癌的促进剂活性
  • 批准号:
    19590127
  • 财政年份:
    2007
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Transcriptional regulation of arylhydrocarbon receptor (AhR), Arnt and E2F genes on proliferation process in A549 cells by dioxin and its mechanism.
二恶英对芳烃受体(AhR)、Arnt和E2F基因转录调控A549细胞增殖过程及其机制
  • 批准号:
    17590109
  • 财政年份:
    2005
  • 资助金额:
    $ 18.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了